日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Development and Verification of Virtual Population Models for Predicting Drug Pharmacokinetics in Ethnic North American Populations

构建和验证用于预测北美不同族裔人群药物药代动力学的虚拟人群模型

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.70068
Ezuruike, Udoamaka; Dinh, Jean; El-Khateeb, Eman; Blenkinsop, Alex; Hatley, Oliver; Gardner, Iain
发表日期：2025
文献求助 收藏

Physiologically Based Pharmacokinetic Modelling to Predict Imatinib Exposures in Cancer Patients with Renal Dysfunction: A Case Study

基于生理药代动力学模型预测肾功能不全癌症患者伊马替尼暴露量：病例研究

期刊:Pharmaceutics
影响因子:5.5
doi:10.3390/pharmaceutics15071922
Rowland Yeo, Karen; Hatley, Oliver; Small, Ben G; Johnson, Trevor N
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator

预测涉及抑制作用的 CYP 介导的药物相互作用：满足 Simcyp 模拟器系统验证要求的方法

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.12794
Kilford, Peter J; Chen, Kuan-Fu; Crewe, Kim; Gardner, Iain; Hatley, Oliver; Ke, Alice Ban; Neuhoff, Sibylle; Zhang, Mian; Rowland Yeo, Karen
发表日期：2022
文献求助 收藏

Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interaction Potential of Vemurafenib Using R-Value and Physiologically-Based Pharmacokinetic Models

利用R值和基于生理的药代动力学模型评估维莫非尼的OATP1B1和OATP1B3介导的药物相互作用潜力

期刊:Journal of Pharmaceutical Sciences
影响因子:3.8
doi:10.1016/j.xphs.2020.06.016
Kayesh, Ruhul; Farasyn, Taleah; Crowe, Alexandra; Liu, Qiang; Pahwa, Sonia; Alam, Khondoker; Neuhoff, Sibylle; Hatley, Oliver; Ding, Kai; Yue, Wei
OAT
ATP1B3
发表日期：2021
文献求助 收藏

Development of physiologically-based pharmacokinetic models for standard of care and newer tuberculosis drugs

开发基于生理的结核病标准治疗药物和新型结核病药物的药代动力学模型

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.12707
Humphries, Helen; Almond, Lisa; Berg, Alexander; Gardner, Iain; Hatley, Oliver; Pan, Xian; Small, Ben; Zhang, Mian; Jamei, Masoud; Romero, Klaus
发表日期：2021
文献求助 收藏

Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions.

用依维莫司和西罗莫司进行预孵育可降低有机阴离子转运多肽 (OATP)1B1 和 1B3 介导的转运，且与 mTOR 激酶抑制无关：对评估 OATP1B1 和 OATP1B3 介导的药物相互作用的意义

期刊:Journal of Pharmaceutical Sciences
影响因子:3.8
doi:10.1016/j.xphs.2019.04.019
Farasyn Taleah, Crowe Alexandra, Hatley Oliver, Neuhoff Sibylle, Alam Khondoker, Kanyo Jean, Lam TuKiet T, Ding Kai, Yue Wei
信号转导
mTOR
发表日期：2019
文献求助 收藏

Quantifying gut wall metabolism: methodology matters

量化肠壁代谢：方法学至关重要

期刊:Biopharmaceutics & Drug Disposition
影响因子:2
doi:10.1002/bdd.2062
Hatley, Oliver J D; Jones, Christopher R; Galetin, Aleksandra; Rostami-Hodjegan, Amin
代谢
发表日期：2017
文献求助 收藏

Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models

预测药物在人体肠壁中的提取：利用临床前模型评估药物代谢酶和转运蛋白的作用

期刊:Clinical Pharmacokinetics
影响因子:4
doi:10.1007/s40262-015-0351-6
Peters, Sheila Annie; Jones, Christopher R; Ungell, Anna-Lena; Hatley, Oliver J D
Human
代谢
发表日期：2016
文献求助 收藏

Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination

肠壁代谢。临床前模型在预测人体药物吸收和首过消除中的应用

期刊:AAPS Journal
影响因子:3.7
doi:10.1208/s12248-016-9889-y
Jones, Christopher R; Hatley, Oliver J D; Ungell, Anna-Lena; Hilgendorf, Constanze; Peters, Sheila Annie; Rostami-Hodjegan, Amin
Human
代谢
发表日期：2016
文献求助 收藏

Animal versus human oral drug bioavailability: do they correlate?

动物与人类口服药物生物利用度：二者之间有相关性吗？

期刊:European Journal of Pharmaceutical Sciences
影响因子:4.7
doi:10.1016/j.ejps.2013.08.018
Musther, Helen; Olivares-Morales, Andrés; Hatley, Oliver J D; Liu, Bo; Rostami Hodjegan, Amin
发表日期：2014
文献求助 收藏